Interim results from the phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) in pancreatic cancer (PC), non-small cell lung cancer (NSCLC), and metastatic breast cancer (mBC). (December 2016) - Wainberg, Z.A.; George, B.; Goldman, J.W.; Hochster, H.S.; Kelly, K.; Ko, A.; O'Dwyer, P.J.; Trunova, N.; Waterhouse, D.; Soliman, H.H.